Treatment and prevention of respiratory syncytial virus infection

European Journal of Pediatrics

Volumn 159, Issue 6, 2000, Pages 399-411

  Kneyber, Martin C J ^a   Moll, Henriëtte A ^a   De Groot, Ronald ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Prevention; Review; RSV; Treatment

Indexed keywords

ADRENALIN; ALPHA2A INTERFERON; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; HYPERIMMUNE GLOBULIN; IPRATROPIUM BROMIDE; LIVE VACCINE; MONOCLONAL ANTIBODY; PALIVIZUMAB; PREDNISOLONE; PREDNISONE; RECOMBINANT VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RETINOL; RIBAVIRIN; SALBUTAMOL;

ANIMAL MODEL; BRONCHODILATATION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; HUMAN; IMMUNOPROPHYLAXIS; INFANT; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; VACCINATION; VIRUS INFECTION;

EID: 0034111033     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004310051296     Document Type: Review

References (148)

1. Aherne W, Bird T, Court SDM, Gardner PS, McQuillin J (1970) Pathological changes in virus infections of the lower respiratory tract in children. J Clin Path 23: 7-18
2. Alario AJ, Lewander WJ, Dennehy P, Seifer R, Mansell AL (1992) The efficacy of nebulized metaproterenol in wheezing infants and young children. Am J Dis Child 146: 412-418
3. American Academy of Pediatrics (1996) Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. Pediatrics 97: 137-140
4. American Academy of Pediatrics (1997) Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics 99: 645-650
5. American Academy of Pediatrics (1998) Prevention of respiratory syncytial virus infections: indications for use of palivizumab and update on the use of RSV-IGIV. Pediatrics 102: 121-1216
6. Barry W, Cockburn F, Cornall R, Prive JF, Sutherland G, Vardag A (1986) Ribavirin aerosol for acute bronchiolitis. Arch Dis Child 61: 593-597
7. Bastien N, Trudel M, Simard C (1997) Protective immune responses induced by the immunisation of mice with a recombinant bacteriophage displaying an epitope of the human respiratory syncytial virus. Virology 234: 118-122
8. Beherendt CE, BD Decker MD, Watson PH for the international RSV study group (1998) International variation in the management of infants hospitalised with respiratory syncytial virus. Eur J Pediatr 157: 215-220
9. Belshe RB, Anderson EL, Walsh EE (1993) Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 168: 1024-1029
10. Belshe RB, van Voris LP, Mufson MA (1982) Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis 145: 311-319
11. Bradley JS, Connor JD, Compogiannis LS, Eiger LL (1990) Exposure of health care workers to ribavirin during therapy for respiratory syncytial virus infections. Antimicrob Agents Chemother 34: 668-670
12. Brandt CD, Kim HW, Arrobio JA, Jeffries BC, Wood SC, Chanock RM et al (1973) Epidemiology of respiratory syncytial virus infection in Washington DC. III: composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol 98: 355-364
13. Cannon MJ, Openshaw PJ, Askonas BA (1988) Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 168: 1163-1168
14. Chevallier B, Aegerter P, Parat S, Bidat E, Renaud C, Lagardère B (1995) Etude comparative des nébulisations de salbutamol contre placebo à la phase aiguë d'une bronchiolite chez 33 nourissons de 1 à 6 mois. Arch Pediatr 2: 11-17
15. Chipps BE, Sullivan WF, Portnoy J (1993) Alpha-2a-interferon for treatment of bronchiolitis caused by respiratory syncytial virus. Pediatr Infect Dis J 12: 653-658
16. Chowdhury D, Al Howasi M, Khalil M, AL-Frayh AD, Chowdhury S, Ramia S (1995) The role of bronchodilators in the management of bronchiolitis: a clinical trial. Ann Trop Pediatr 15: 77-84
17. Connolly JH, Field CMB, Glasgow JFT, Slattery CM, MacLynn DM (1969) A double blind trial of prednisolone in epidemic bronchiolitis due to respiratory syncytial virus. Acta Paediatr Scand 58: 116-120
18. Connor J (1990) Ribavirin pharmacokinetics. Pediatr Infect Dis J 9: S91-S92
19. Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse III HC, Murphy BR (1994) Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunised BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68: 5321-5325
20. Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse III HC, Sotnikov AV, et al (1992) Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactived RSV-immunised BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 66: 7444-7451
21. Conrad DI, Christenson JC, Waner JL, Marks MI (1987) Aerosolised ribavirin treatment of respiratory syncytal virus infection in infants hospitalised during an epidemic. Pediatr Infect Dis J 6: 152-158
22. Crowe Jr JE (1998) Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines. Vaccine 16: 1423-1432
23. Crowe Jr JE, Bui PH, Siber GR, Elinks WR, Chanock RM, Murphy BR (1995) Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunisation. Vaccine 13: 847-855
24. Crowe Jr JE, Gilmour PS, Murphy BR, Chanock RM, Duan L, Pomerantz RJ et al (1998) Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. J Infect Dis 177: 1073-1076
25. Crowe JR JE, Murphy BR, Chanock RM, Williamson RA, Barbas CF, Burton DR (1994) Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci USA 91: 1386-1390
26. Crowe Jr JE, Phuong TB, Davis R, Chanock RM, Murphy BR (1994) A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus (RSV cpts-248) retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12: 783-790
27. Dargaville PA, South M, McDougall PN (1996) Surfactant abnormalities in infants with severe viral bronchiolitis. Arch Dis Child 75: 133-136
28. DeVicenzo J (1998) Prevention and treatment of respiratory syncytial virus infections (for advances in pediatric infectious diseases). Adv Pediatr Infect Dis 13: 1-47
29. Dudas RA, Karron RA (1998) Respiratory syncytial virus vaccines. Clin Microbiol Rev 11: 430-439
30. Edell D, Bruce E, Hale K, Edell D, Khoshoo V (1998) Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report. Pediatr Pulmonol 25: 154-158
31. Englund JA, Glezen WP, Piedra PA (1998) Maternal immunisation against viral disease. Vaccine 16: 1456-1463
32. Englund JA, Piedra PA, Ahn YM, Gilbert BE, Hiatt P (1994) High-dose, short-duration ribavirin aerosol therapy compared with standard ribavirin therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr 125: 635-641
33. Everard ML, Swarbrick A, Wrightham M, McIntyre J, Dunkley C, James PD, et al (1994) Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 71: 428-432
34. Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, et al (1996) The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanised monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 174: 463-469
35. Fernandez H, Banks G, Smith R (1986) Ribavirin: a clinical overview. Eur J Epidemiol 2: 1-14
36. Flores, Horwitz RI (1997) Efficacy of β2-agonists in bronchiolitis: a reappraisal and meta-analysis. Pediatrics 100: 233-239
37. Fulginit VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G (1969) Respiratory virus immunisation. I: a field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89: 435-448
38. Gadomski AM, Aref GH, Badr El Din O, El Sawy IH, Khallaf N, Black RE (1994) Oral versus nebulized albuterol in the management of bronchiolitis in Egypt. J Pediatr 124: 131-138
39. Gadomski AM, Lichenstein R, Orton L, King J, Keane V, Permutt T (1994) Efficacy of albuterol in the management of bronchiolitis. Pediatrics 93: 907-912
40. Graham BS, Bunton LA, Wright PF, Karzon DT (1991) Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 88: 1026-1033
41. Groothuis JR, Gutierrez KM, Lauer BA (1988) Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 82: 199-203
42. Groothuis JR, Levin MJ, Rodriguez W, Hall CB, Long CE, Kim HW, et al (1991) Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob Agents Chemother 35: 1469-1473
43. Groothuis JR, Simoes EAF, Hemming VG and the respiratory syncytial virus immune globulin study group (1995) Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Pediatrics 95: 463-467
44. Groothuis JR, Simoes EAF, Levin MJ, Hall CB, Long CE, Rodriguez WJ, et al (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329: 1524-1530
45. Groothuis JR, Woodin KA, Katz R, Robertson AD, McBride JT, Hall CB, et al (1990) Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. J Pediatr 117: 792-798
46. Hall CB (1985) Ribavirin: beginning the blitz on respiratory viruses? Pediatr Infect Dis 4: 668-671
47. Hall CB (1994) Prospects for a respiratory syncytial virus vaccine. Science 265: 1393-1394
48. Hall CB, Douglas Jr RG, Simons RL, G JM (1978) Interferon production in children with respiratory syncytial virus, influenza, and parainfluenza virus infections. J Pediatr 93: 28-32
49. Hall CB, McBride JT, Gala CL, Hildreth SW, Schnabel KC (1985) Ribavirin treatment of respiratory syncytal viral infection in infants with underlying cardiopulmonary disease. JAMA 254: 3047-3051
50. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S, et al (1983) Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection: a randomised double-blind study. N Engl J Med 308: 1443-1447
51. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus, Suffin SC, et al (1986) Respiratory syncytial virus infection in children with compromised immune function. N Engl J Med 315: 77-81
52. Hall CB, Powell KR, Schnabel KC, Gala CL, Pincus PH (1988) Risk of secondary bacterial infection in infants hospitalised with respiratory syncytial viral infection. J Pediatr 113: 266-271
53. Hall CB, Stevens TP, Swantz RJ, Sinkin RA, McBride JT (1999) Development of local guidelines for prevention of respiratory syncytial viral infections. Pediatr Infect Dis J 18: 850-853
54. Hammer J, Numa A, Newth CJL (1995) Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection. J Pediatr 127: 485-490
55. Hay JW, Ernst RL, Meissner HC (1996) Respiratory syncytial virus immune globulin: a cost-effectiveness analysis. Am J Managed Care 2: 851-861
56. Hebert MF, Guglielmo BJ (1990) What is the clinical role of aerosolized ribavirin. DICP 24: 735-738
57. Heilman C (1990) Respiratory syncytial and parainfluenza viruses. J Infect Dis 161: 402-406
58. Hemming VG, Prince GA (1986) Intravenous immunoglobulin G in viral respiratory infections for newborns and infants. Pediatr Infect Dis J 5: S204-S206
59. Hemming VG, Prince GA, Rodriguez W, Kim HW, Brandt CD, Parrott RH, et al (1988) Respiratory syncytial virus infections and intravenous gamma-globulins. Pediatr Infect Dis J 7: S103-S106
60. Henry RL, Milner AD, Stokes GM (1983) Ineffectiveness of ipratropium bromide in acute bronchiolitis. Arch Dis Child 58: 924-926
61. Higgins PG, Barrow GI, Tyrell DAJ, Isaacs D, Gauci CL (1990) The efficacy of intranasal Interferon α-2a in respiratory syncytial virus infection in volunteers. Antiviral Res 14: 3-10
62. Ho L, Collis G, Landau LI, Le Souef PN (1991) Effect of salbutamol on oxygen saturation in bronchiolitis. Arch Dis Child 66: 1061-1064
63. IMPACT-RSV Study Group (1998) Palivizumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531-537
64. Janai HK, Stutman HR, Zaleska M, Rub B, Eyzaguirre M, Marks MI, et al (1993) Ribavirin effect on pulmonary function in young infants with respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J 12: 214-218
65. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, et al (1997) Development of a humanised monoclonal antibody (MEDI-439) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176: 1215-1224
66. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial virus (RSV) infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89: 405-421
67. Karron RA, et al (1999) Evaluation of live recombinant RSV A2 vaccines in children over 6 months of age. In: RSV after 43 years, Stuart, Florida
68. Karron R A, Wright PF, Crowe Jr JE, Clements ML, Thompson J, Makhene M, et al (1997) Evaluation of two live, cold -passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and human adults, infants and children. J Infect Dis 176: 1428-1436
69. Kellner JD, Ohlsson A, Gadomski AM, Wang EEL (1996) Efficacy of bronchodilator therapy in bronchiolitis. a meta-analysis. Arch Pediatr Adolesc Med 150: 1166-1172
70. Kellner JD, Ohlsson A, Gadomski AM, Wang EEL (1999) Bronchodilators for bronchiolitis (Cochrane review). In: The Cochrane Library, Issue 4. Oxford: Update Software
71. Kim HW, Arrobio JO, Brandt CD, Jeffries BC, Pyles G, Reid JL, et al (1973) Epidemiology of respiratory syncytial virus infection in Washington DC: importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. Am J Epidemiol 98: 216-225
72. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactived vaccine. Am J Epidemiol 89: 422-434
73. Kimpen JLL, Garofalo R, Welliver RC, Ogra PL (1992) Activation of human eosinophils in vitro by respiratory syncytial virus. Pediatr Res 32: 160-164
74. Kimpen JLL, Schaad UB (1997) Treatment of respiratory syncytial virus bronchiolitis: 1995 poll members of the European Society for Paediatric Infectious Diseases. Pediatr Infect Dis J 16: 479-481
75. Klassen TP, Rowe PC, Sutcliffe T, Ropp LJ, McDowell IW, Li MM (1991) Randomized trial of salbutamol in acute bronchiolitis. J Pediatr 118: 807-811
76. Klassen TP, Sutcliffe T, Watters LK, Wells GA, Allen UD, Li MM (1997) Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a randomized, controlled trial. J Pediatr 130: 191-196
77. Kneyber MCJ, Brandenburg AH, Groot R de, Rothbarth PhH, Ott A, Moll HA (1996) Relationship between clinical severity of RSV infection and subtype. Arch Dis Child 75: 137-140
78. Krilow LR, Mandel FS, Barone SR, Fagin JC and the bronchiolitis study group (1997) Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long-term pulmonary function. Pediatr Infect Dis J 16: 273-276
79. Kristjánsson S, Lødrup Carlsen KC, Wennergren G, Strannegård I-L, Carlsen K-H (1993) Nebulised racemic adrenaline in the treatment of acute bronchiolitis in infants and toddlers. Arch Dis Child 69: 650-654
80. La Via WV, Marks MI, Stutman HR (1992) Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment and prevention. J Pediatr 121: 503-510
81. Law BJ, Wang EEL, MacDonald N, McDonald J, Dobson S, Boucher F, et al (1997) Does ribavirin impact on the hospital course of children with respiratory syncytial virus infection? An analysis using the pediatric investigators collaborative network on infections in Canada (PICNIC) RSV database. Pediatrics 99: e7
82. Leer JA, Green JL, Heimlich EM, Hyde JS, Moffet HL, Young GA, et al (1969) Corticosteroid treatment in bronchiolitis. Am J Dis Child 117: 495-503
83. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA (1982) Respiratory syncytial virus infection in infants with congenital heart disease. N Engl J Med 307: 397-400
84. Mahata MC, Johnson JA, Powell DA (1985) Management of bronchiolitis. Clin Pharm 4: 297-303
85. McColl MD, Corser RB, Bremner J, Chopra R (1998) Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant 21: 423-425
86. McGowan JR JE, Chesney PJ, Crossley KB, LaForce FM (1992) Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. Working group on steroid use, antimicrobial agents committee, infectious diseases society of America. J Infect Dis 165: 1-13
87. McKay E, Higgins P, Tyrrel D, Pringle C (1988) Immunogenicity and pathogenicity of temperature-sensitive modified respiratory syncytial virus in adult volunteers. J Med Virol 25: 411-421
88. Meert KL, Sarnaik AP, Gelmini M, Lieh-Lai M (1994) Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial. Crit Care Med 22: 566-572
89. Meissner HC, Fulton DR, Groothuis JR, Geggel RL, Marx GR, Hemming VG, et al (1993) Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 37: 1655-1658
90. Moler FW (1999) RSV immune globulin prophylaxis: An ounce of prevention worth an ounce of care? Pediatrics 104: 559-560
91. Moler FW, Brown RW, Faix RG, Gilsdorf JR (1998) Comments on Palivizumab (Synagis). Pediatrics 100: 495-497
92. Moler FW, Steinhart CM, Ohmit SE, Stidham GL for the pediatric critical care study group (1996) Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. J Pediatr 128: 422-428
93. Murphy BR, Walsh EE (1988) Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26: 1595-1597
94. Neuzil KM, Gruber WC, Chytil F, Stahlman MT, Graham BT (1995) Safety and pharmacokinetics of vitamin A therapy for infants with respiratory syncytial virus infections. Antimicrob Agents Chemother 39: 1191-1193
95. Ohmit SE, Moler FW, Monto AS, Khan AS (1996) Ribavirin utilisation and clinical effectiveness in children hospitalised with respiratory syncytial virus infection. J Clin Epidemiol 49: 963-967
96. Openshaw PJM (1995) Immunity and immunopathology to respiratory syncytial virus. The mouse model. Am J Respir Crit Care Med 152: S59-S62
97. O'Shea TM, Sevick MA, Givner LB (1998) Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalisation for lower respiratory tract illness in very low birth weight infants. Pediatr Infect Dis J 17: 587-593
98. Oski FA, Salitsky S, Barness LA (1961) Steroid therapy in bronchiolitis: a double blind study (abstract). Am J Dis Child 102: 759A
99. Piazza FM, Johnson SA, Ottoline MG, Schmidt J, Darnell MER, Hemming VG, et al (1992) Immunotherapy of respiratory syncytial virus infection in cotton rats (sigmodon fulviventer) using IgG in a small-particle aerosol. J Infect Dis 166: 1422-1424
100. Piedra PA, Faden HS, Camussi G, Wong DT, Ogra PL (1989) Mechanism of lung injury in cotton rats immunised with formalin-inactived respiratory syncytial virus. Vaccine 7: 34-38
101. Piedra PA, Grace S, Jewell A, Spinelli S, Bunting D, Hogerman DA, et al (1996) Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 15: 23-31
102. Pinnock CB, Douglas RM, Martin AJ, Badcock NR (1988) Vitamin A status of children with a history of respiratory syncytial virus infection in infancy. Aust Pediatr J 24: 286-289
103. Portnoy J, Hicks R, Pacheco F, Olson L (1988) Pilot study of recombinant Interferon alpha-2a for treatment of infants with bronchiolitis induced by respiratory syncytial virus. Antimicrob Agents Chemother 32: 589-291
104. Power UF, et al (1999) Safety and immunogenicity of a recombinant subunit vaccine against RSV. In: RSV after 43 years, Stuart, Florida
105. Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Stahl S, et al (1997) Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 230: 155-166
106. Prevent Study Group (1997) Reduction of respiratory syncytial virus hospitalisation among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99: 93-99
107. Prince GA, Hemming VG, Horswood RL, Baron PA, Chanock RM (1987) Effectiveness of topically administered neutralising antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol 61: 1851-1854
108. Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, et al (1986) Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactived virus. J Virol 57: 721-728
109. Quinlan KP, Hayani KC (1996) Vitamin A and respiratory syncytial virus infection. Arch Paediatr Adolesc Med 150: 25-30
110. Randolph AG, Wang EEL (1996) Ribavirin for respiratory syncytial virus lower respiratory tract infection. Arch Pediatr Adolesc Med 150: 942-947
111. Randolph AG, Wang EEL (1999) Ribavirin for respiratory syncytial virus infection of the lower respiratory tract (Cochrane review). In: The Cochrane Library, Issue 4. Oxford: Update Software
112. Richter H, Seddon P (1998) Early nebulized budesonide in the treatment of bronchiolitis and the prevention of postbronchiolitic wheezing. J Pediatr 132: 849-853
113. Robbins JM, Tilford JM, Jacobs RF, Wheeler JG, Gillaspy ST, Schutze GE (1998) A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalisation. Arch Pediatr Adolesc Med 152: 358-366
114. Rodriguez WJ, Gruber WC, Groothuis JR, Simoes EAF, Rosas AJ, Lepow M, et al (1997) Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 100: 937-942
115. Rodriguez WJ, Kim HW, Brandt CD, Fink RJ, Getson PR, Arrobio J, et al (1987) Aerosolised ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J 6: 159-163
116. Rodriquez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EAF, Meissner HC, et al (1997) Respiratory synytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections. Pediatrics 99: 454-461
117. Roosevelt G, Sheehan K, Grupp-Phelan J, Tanz RR, Listemick R (1996) Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet 348: 292-295
118. Rosner IK, Welliver RC, Edelson PJ, Geraci-Ciardullio K, Sun M (1987) Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection. J Infect Dis 155: 1043-1047
119. Routledge EG, Willcocks MM, Samson ACR, Morgan L, Scott R, Andersen JJ, et al (1988) The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice. J Gen Virol 69: 293-303
120. Saez-Llorens X, Castano E, Null D, Stiechen J, Sanchez PJ, Ramilo O, et al (1998) Safety and pharmacokinetics of an intramuscular humanised monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 17: 787-791
121. Saijo M, Ishii T, Kokubo M, Murono K, Takimoto M, Fujita K (1996) White blood cell count, C-reactive protein and erythrocyte sedimentation rate in respiratory syncytial virus infection of the lower respiratory tract. Acta Pediatr Jpn 38: 596-600
122. Schuh S, Johnson D, Canny G, Reisman J, Shields M, Kovesi T, et al (1992) Efficacy of adding nebulized ipratropium bromide to nebulized albuterol therapy in acute bronchiolitis. Pediatrics 90: 920-923
123. Seidenberg J, Masters IB, Hudson I, Olinsky A, Phelan PD (1987) Effect of ipratropium bromide on respiratory mechanics in infants with acute bronchiolitis. Aust J Pediatr 23: 169-172
124. Siber GR (1992) Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis 165: 456-463
125. Siber GR, Leombruno D, Leszczynski J, McIver J, Bodkin D, Gonin R, et al (1994) Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. J Infect Dis 169: 1368-1373
126. Simoes EAF, Sondhiemer HM, Top FH, Meissner HC, Welliver RC, Kramer AA, et al (1998) Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr 133: 492-499
127. Smith DW, Frankel LR, Mathers LH, TAng ATS, Ariagno RL, Prober CG (1991) A controlled trial of aerosolised ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 325: 24-29
128. Soto ME, Sly PD, Uren E, Taussig LM, Landau LI (1985) Bronchodilator resonse during acute viral bronchiolitis in infancy. Pediatr Pulmonol 1: 85-91
129. Springer C, Bar-Yishay E, Uwayyed K, Avital A, Vilozni D, Godfrey S (1990) Corticosteroids do not affect the clinical or physiological status of infants with bronchiolitis. Pediatr Pulmonol 9: 181-185
130. Stott EJ, Taylor G, Jebbett J, Collins AP (1984) The characterisation and uses of monoclonal antibodies to respiratory syncytial virus. Dev Biol Stand 57: 237-244
131. Subramanian KNS, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, et al (1998) Safety, tolerance and pharmacokinetics of a humanised monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J 17: 110-115
132. Sussman S, Grossman M, Magoffin R (1966) Dexamethasone in obstructive respiratory tract infections in children. Pediatrics 34: 851-855
133. Taber LH, Knight V, Gilbert BE, McClung HW, Wilson SZ, Norton HJ, et al (1983) Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics 72: 613-618
134. Tal A, Bavilski C, Yohai D, Bearman JE, Gorodischer R, Moses SW (1983) Dexamethasone and salbutamol in the treatment of acute wheezing in infants. Pediatrics 71: 13-18
135. Taylor G, Stott EJ, Bew M, Fernie BF, Cote PJ (1983) Monoclonal antibodies protect against respiratory syncytial virus. Lancet 2: 976
136. Teele DW, Marshall R, Klein DO (1979) Unsuspected bacteremia in young children: a common and important problem. Pediatr Clin North Am 26: 773-784
137. Tepper RS, Rosenberg D, Eigen H, Reister T (1994) Bronchodilator responsiveness in infants with bronchiolitis. Pediatr Pulmonol 17: 81-85
138. Tristram DA, Welliver RC, Mohar CK, Hogerman DA, Hildreth SW, Paradiso P (1993) Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 167: 191-195
139. van Woensel JBM, Wolfs TFW, van Aalderen WMC, Brand PLP, Kimpen JLL (1997) Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis. Thorax 52: 634-637
140. Walsh EE (1993) Mucosal immunisation with a subunit respiratory syncytial virus vaccine in mice. Vaccine 11: 1135-1138
141. Walsh EE (1994) Humoral, mucosal, and cellular immune response to topical immunisation with a subunit respiratory syncytial virus vaccine. J Infect Dis 170: 345-350
142. Walsh EE, Schlesinger JJ, Brandriss MW (1984) Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 43: 756-758
143. Wang EEL, Law BJ (1998) Respiratory syncytial virus infection in paediatric patients. Sem Pediatr Infect Dis 9: 146-153
144. Wang EEL, Milner R, Allen U, Maj H (1992) Bronchodilators for treatment of mild bronchiolitis: a factorial randomised trial. Arch Dis Child 67: 289-293
145. Wang EEL, Tang NK (1999) Immunoglobulin for preventing respiratory syncytial virus infection (Cochrane review). In: The Cochrane Library, Issue 4. Oxford: Update Software
146. Welliver RC, Tristram DA, Batt K, Sun M, Hogreman D, Hildreth S (1994) Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion subunit vaccine. J Infect Dis 170: 425-428
147. Weltzin R, Hsu SA, Mittler ES, Georgakopoulos K, Monath TP (1994) Intranasal monoclonal immunoglobulin A against respiratory syncytial virus protects against upper and lower respiratory tract infections in mice. Antimicrob Agents Chemother 38: 2785-2791
148. Wheeler JG, Wofford J, Turner RB (1993) Historical cohort evaluation of ribavirin efficacy in respiratory syncytial virus infection. Pediatr Infect Dis J 12: 209-213